Scarica l'app Stockscreener
4.27
1.61%
-0.07
Pre-mercato:
4.34
0.07
+1.64%
Immuneering Corp Borsa (IMRX) Ultime notizie
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering to Present at the ESMO Congress 2026 - The Manila Times
A pancreatic cancer drug combination is in a late-stage study. Its trial plan will be shown in Madrid. - Stock Titan
Immuneering Corporation(NasdaqGM: IMRX) added to S&P Global BMI Index - marketscreener.com
Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us
Immuneering at H.C. Wainwright conference: pancreatic cancer push By Investing.com - Investing.com Nigeria
Immuneering at H.C. Wainwright conference: pancreatic cancer push - Investing.com
Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus - Investing.com Canada
Immuneering Stock (IMRX) Opinions on Pancreatic Cancer Drug Presentation - Quiver Quantitative
Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference - Quiver Quantitative
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival - The Manila Times
84% of evaluable pancreatic cancer patients kept or gained weight after three months - Stock Titan
Immuneering to Participate in Upcoming Investor Conferences - Yahoo Finance
H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential - Investing.com India
Immuneering comments on FDA pancreatic cancer drug approval By Investing.com - Investing.com India
Immuneering Highlights FDA Approval in Second-Line Pancreatic Cancer as Phase 3 MAPKeeper 301 Enrolls First-Line Patients - Quiver Quantitative
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - barchart.com
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
HC Wainwright Estimates Immuneering Q3 Earnings - MarketBeat
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat
Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India
HC Wainwright Initiates Immuneering at Buy With $14 Price Target - Yahoo Finance
Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com
Immuneering Corporation Q2 Net Income USD -17 - moomoo.com
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Income Statement - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX) Cash Flow - TradingKey
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times
Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options - Stock Titan
Immuneering Corporation Announces Inducement Equity Grants to New CFO and Employee - Quiver Quantitative
Immuneering’s New CFO Gets 650,000-Share Option With $4.78 Exercise Price - Stock Titan
Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares - Stock Titan
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):